Pasadena, CA, United States
Pasadena, CA, United States

Time filter

Source Type

Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising interleukin 12 (IL-12) useful for treating radiation-induced damage in a subject. In particular, the instant disclosure provides methods and compositions for radiation protection and/or radiation toxicity mitigation for the treatment of acute radiation syndrome and radiation induced toxicity associated with the treatment of cutaneous T-cell lymphoma.


The present invention is directed to methods of using HSS1 (Hematopoietic Signal peptide-containing Secreted 1), HSM1 (Hematopoietic Signal peptide-containing Membrane domain-containing 1), or a combination thereof in the treatment of various cancers, such as brain cancers.


Patent
Neumedicines Inc. | Date: 2014-12-19

The present invention provides methods for increasing survival in a subject, and/or preserving bone marrow function, and/or promoting hematopoietic recovery or restoration. The methods include administering a dose of IL-12 to the subject following an acute exposure to non-therapeutic whole body ionizing radiation. Formulations and kits are also provided.


Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising inter-leukin 12 (IL-12) useful for treating radiation-induced damage in a subject. In particular, the instant disclosure provides methods and compositions for radiation protection and/or radiation toxicity mitigation for the treatment of acute radiation syndrome and radiation induced toxicity associated with the treatment of cutaneous T-cell lymphoma.


Patent
Neumedicines Inc. | Date: 2014-03-13

The present invention is directed to an endogenous vaccine targeted to a cancer or an infectious disease.


Patent
Neumedicines Inc. | Date: 2015-10-30

Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising interleukin 12 (IL-12) useful for improving hematopoietic recovery HSCT transplantation in a subject. In particular, the instant disclosure provide exemplary methods and compositions comprising IL-12 promoted hematopoiesis and increased the recovery of peripheral blood cells and survival in lethally irradiated mice as effectively as a BMCT, indicating that rHuIL-12 therapy can to increase HSC engraftment following HSCT. We identified IL-12R2 expressing cells in irradiated mouse bone marrow which are potential targets of IL-12. Administration of rMuIL-12 increased the number of IL-12R2 expressing Lin cells in mouse bone marrow, indicating that bone marrow HSCs and niche cells are the direct target of rMuIL-12 and that hematopoiesis-promoting activity of rMuIL-12 is mediated by IL-12 receptors on HSCs. Finally, we show expression of IL-122 on human bone marrow lin and CD34+ cells, indicating a potential role for IL-12 in human transplantation.


Patent
Neumedicines Inc. | Date: 2015-10-30

Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising interleukin 12 (IL-12) as a hematopoietic immunotherapy (HIT) useful for treating or preventing a cancer patient from chemotherapy-induced cytopenias necessitating a dose reduction and/or dose delay. following exposure of the patient to chemotherapeutic agents, the method comprising: administering a dose of therapeutically effective amount of a pharmaceutical composition comprising substantially isolated IL-12 to the subject, whereby cytopenias are reduced and leading to increases responses to the chemotherapy agent(s).diminished.


The present application relates to methods of treating cancer using compositions comprising Hematopoietic Signal peptide-containing Secreted 1 (HSS1), derivatives of HSS1. Hematopoietic Signal peptide-containing Membrane domain-containing 1 (HSM1), derivatives of HSM1, or any combination thereof.


The present application relates to stem cells isolated from various sources within the body of a patient or of a healthy donor and identified by the presence of the interleukin 12 (IL-12) receptor. The present application also provides methods for making and for using the stem cells.


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase II | Award Amount: 1.51M | Year: 2015

DESCRIPTION provided by applicant Cutaneous T cell lymphoma CTCL is a chronic incurable disease with significant morbidity and mortality Treatment of CTCL depends on clinical stage and includes both topical and systemic therapies including psoralene plus UVA irradiation PUVA total skin electron beam therapy TSEBT systemic chemotherapy and newly approved drugs vorinostat romidepsin and pralatrexate which have been FDA approved based on overall response rates of to These interventions are associated with sometimes debilitating and dose limiting side effects and are not curative Partial responses progression and relapses do often occur and prolonged disease free survival is rare except in patients with early stage CTCL CTCL is highly responsive to radiotherapy and TSEBT has evolved as a powerful treatment regimen Current low dose Gy TSEBT treatment regimens can generate very good responses with minimal toxicity However relapses occur and doses are gradually increased High dose Gy treatment regimens of are commonly used resulting in complete response CR rates ranging from in limited plaque stage to in tumor stage The CR rate is correlated with total radiation dose but most patients will eventually relapse However high dose TSEBT is generally not repeated more than twice due to the concern of causing significant toxicity such as skin atrophy and necrosis In phase I and phase II clinical studies interleukin IL monotherapy was shown to be effective in CTCL inducing tumor regression and achieving some complete responses Recombinant human interleukin rHuIL has also been shown to be effective as a mitigator of radiation induced hematopoietic and skin toxicity Figures With rHuIL we propose to induce significant antitumor clinical responses in synergy with the radiation therapy while providing radiation protection to normal tissues rHuIL is an optimal adjuvant for radiation therapy in CTCL for several reasons rHuIL effectively mitigates radiation side effects Figures rHuIL exhibits independent antitumor activity in CTCL Fig and together with radiation induced immunogenic tumor cell death rHuIL modulates tumor microenvironment to potentiate tumor antigen uptake and presentation by APCs blocks activity of cells capable of immune suppression resulting in a Th skewing and antitumor stimulating immune environment leading to long lasting antitumor immunity likely via an endogenous vaccine effect Fig The proposed project is a phase I clinical study of rHuIL in combination with TSEBT in patients with CTCL The specific aims or objectives of the project are Determine the safety of rHuIL in patients with CTCL treated with low dose TSEBT Establish a recommended phase II dose RP D of rHuIL and Explore efficacy endpoints of rHuIL in patients with CTCL treated with low dose TSEBT PUBLIC HEALTH RELEVANCE CTCL has no cure In the past years new drugs vorinostat romidepsin and pralatrexate have been approved for use in CTCL treatment but all have substantial sometimes debilitating adverse effects have limited efficacy response rate and do not provide long term remissions from the disease We propose that a novel immunotherapy recombinant human interleukin rHuIL in combination with radiation therapy total skin electron beam therapy or TSEBT has potential to significantly improve the current CTCL treatment paradigm by improving rates of complete response and relapse free survival via simultaneously stimulating oneandapos s own immune system against cancer cells and protecting healthy skin tissue against the toxicity of standard use radiation therapy The proposed project is a phase I clinical study of rHuIL in combination with radiation therapy TSEBT in patients with CTCL

Loading Neumedicines Inc collaborators
Loading Neumedicines Inc collaborators